Adult orbital tumor
A Southeast Asian experience
Aim: to study the prevalence, demographics, clinical and histolopathological features of orbital tumors biopsied in Hospital Serdang, a national Oculoplastic referral centre in Malaysia.
Methods: A retrospective, observational study on all the consecutive orbital biopsies performed in Hospital Serdang from January 2008 to December 2014. Outcome measurement includes demographic data and histological diagnosis of biopsied orbital lesions.
Results: Among a total of 136 cases, there is slight male preponderence (59.6%). Malay is the commonest racial group (58.8%) followed by Chinese (32.4%). Lymphoproliferative lesion is the most common category (34.6%) followed by inflammatory (10.3%) and lacrimal lesion (9.6%). Benign lymphoid hyperplasia (16.9%) and Non Hodgkin lymphoma(BHL) (16.2%) were the most common histology diagnosis. Those with benign lymphoid hyperplasia developed at a younger age (mean 56 years) compared to those with Non Hodgkin Lymphoma (60.6 years old). Benign lymphoid hyperplasia occurred at a same frequency at orbit and lacrimal gland whilst those NHL were mostly located within the orbit. Lymphoproliferative disorders are more common among male and Chinese. Our patients develop cavernous haemangioma, pleomorphic adenoma and solitary fibrous tumor at an earlier age than Western counterparts. Benign orbital lesions whilst being more common, may be associated with significant visual and orbital comorbidities.
Conclusions: Lymphoproliferative lesions occur at a higher occurrence among Souteast Asian patients, especially among Chinese and male. Our patients also develop cavernous haemangioma, pleomorphic adenoma and solitary fibrous tumor at an earlier age compared to their Western counterparts. There is ethnic difference among different orbital pathologies. Delayed presentation of benign orbital lesions lead to significant morbidity and sometimes exenteration. Financial restraints may hinder clinicians in developing countries to obtain precise histological diagnosis.
2. Karcioglu ZA, Remus LE, III. Orbital biopsy. In: Karcioglu ZA (ed.), Orbital tumor diagnosis and treatment. First edition, pp. 113-129. New York: Springer 2009.
3. Ho-Seok Sa, Ju Hyang Lee, Kyung In Woo, Yoon Duck Kim. Ig G4 related disease in idiopathic sclerosing orbital inflammation. Br J Ophthalmol (epub online May 6, 2015).
4. Bonavolonta G, Strianese D, Grassi P, et al. An analysis of 2480 space-occupying lesions of the orbit from 1976 to 2011. Ophthal Plast Reconstr Surg 2013;29(2):79-86.
5. Johansen S, Heegaard S. Bogeskov L, Prause JU. Orbital space-occupying lesions in Denmark 1974-1997. Acta Ophthalmol Scand 2000;78(5):547-552.
6. Demirci H, Shields CL, Shields JA, et al. Orbital tumors in the older adult population. Ophthalmology 2002;109(2):243-248.
7. Shinder R, Al-Zubidi N, Esmaeli B. Survey of orbital tumors at a comprehensive cancer centre in the United States. Head Neck 2011;33(5):610-614.
8. Shikishima K, Kawai K, Kitaharn K. Pathological evaluation of orbital tumor in Japan: an analysis of a large case series and 1379 cases reported in Japanese literature. Clin Exp Ophthalmol 2006;34(3):239-244.
9. Ni C, Ma X. Histopathologic classification of 1921 orbital tumors. Yan Ke que Bao 1995;11(2):101-104
10. Holzer MP, Solomon KD, Sandoval HP, Vroman DT. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg 2002;28:93-99.
11. Miyanaga M, Miyai T, Nejima R, et al. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 2009;87:300-305.
12. Missotten L, Richard C, Trinquand C. Topical 0.1% indomethacin solution versus topical
0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. Ophthalmologica 2001;215:43-50.
13. Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and bloodaqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0. 1%. J Cataract Refract Surg 2008;34:57-63.
14. Miyake K, Ota I, Miyake G, Numaga J. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. J Cataract Refract Surg 2011;37:1581-1588.
15. Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol (Auckland, NZ) 2011;5:811.
16. Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated
phacoemulsification surgery by optical coherence tomography. Curr Eye Res 2007;32:241-247.
17. Nicholas S, Riley A, Patel H, et al. Correlations between optical coherence tomography measurement of macular thickness and visual acuity after cataract extraction. Clin Experiment Ophthalmol 2006;34:124-129.
18. Ching HY, Wong AC, Wong CC, et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye (Lond) 2006;20:297-303.
19. Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution. A double-masked, paired comparison with vehicle-placebo solution study. Arch Ophthalmol 1988;106:344-347.
20. Sancilio LF, Nolan JC, Wagner LE, Ward JW. The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 1987;37(5):513-519.
21. Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens 2008;34:129-130.
22. Ching HY, Wong AC, Wong CC, et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye (Lond) 2006;20:297-303.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication, with the work twelve (12) months after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).